title: Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.
abstract: OBJECTIVE
  Fosaprepitant is known to cause infusion-site reactions. However, there is limited data regarding these reactions including the effect of peripheral intravenous administration or other potential factors on their incidence. This single-institution retrospective study was undertaken to investigate the incidence of infusion-site reactions with single-dose intravenous (IV) fosaprepitant when given through a peripheral line prior to administration of chemotherapy. Risk factors for the development of infusion-site reactions with fosaprepitant were also explored.
  
  
  METHODS
  Medical records of patients with cancer receiving IV fosaprepitant through a peripheral line were reviewed. The primary objective of this study was to estimate the incidence of infusion-site reactions at our institution. Data collection included demographics, fosaprepitant infusion information, and grading of reactions.
  
  
  RESULTS
  We found a 15 % incidence of infusion-site reactions among all peripherally administered doses of fosaprepitant. The 50 reactions occurred in 43 unique patients representing an incidence per patient of 28.7 % (43/150; 95 % confidence interval (CI) 21.6-36.6). Factors found to be associated with infusion-site reactions included age [odds ratio (OR) 0.97 (95 % CI 0.94-0.99)], location of IV line [OR forearm vs. hand 0.41 (95 % CI 0.20-0.85); OR antecubital fossa vs. hand 0.31 (95 % CI 0.11-0.87)], and simultaneous maintenance IV fluid rate ≥100 mL/h during fosaprepitant infusion [OR 0.19 (95 % CI 0.08-0.44)].
  
  
  CONCLUSIONS
  The incidence of infusion-site reactions with peripherally administered fosaprepitant as seen in this study is higher than that reported in the package insert. Risk factors for developing infusion-site reactions in our patient population include age, location of IV line, and simultaneous maintenance IV fluid rate of <100 mL/h.
authors.affiliation: The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University, 410 W 10th Ave, 368 Doan Hall, Columbus, OH, 43210, USA, jordan.lundberg@osumc.edu.
authors.forename: Jordan D
authors.initials: JD
authors.lastname: Lundberg
authors.forename: Brooke Sorgen
authors.initials: BS
authors.lastname: Crawford
authors.forename: Gary
authors.initials: G
authors.lastname: Phillips
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Berger
authors.forename: Robert
authors.initials: R
authors.lastname: Wesolowski
mesh_terms: D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000008:administration & dosage* / Q000009:adverse effects*; D005260:Female; D006801:Humans; D015994:Incidence; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000008:administration & dosage* / Q000009:adverse effects*; D009369:Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies
chemical_list: D000932:Antiemetics; D009025:Morpholines; C579707:fosaprepitant